Ones To Watch News
Refine Search
Pharmaceutical
Sweden’s Moberg Pharma has entered into an exclusive licensing agreement with Karo Healthcare regarding the commercialization of MOB-015 (Terclara) in Europe. 5 November 2025
Biotechnology
Italy based clinical-stage biotech AAVantgarde Bio today announced the successful closing of a $141 million (122 million euros) Series B financing round. 4 November 2025
Pharmaceutical
The bidding war for US obesity focused biotech Metsera, which has attracted offers from Pfizer and Novo Nordisk , and resulted in lawsuits by the US giant taking legal action against the Danish firm and Metsera, has taken a further step. 4 November 2025
Pharmaceutical
UK biotech Slingshot Therapeutics, part of the Syncona Accelerator, has expanded its senior team with the appointments of John Isaac as chief scientific officer and Bobby Soni as chief business officer. The move supports the company’s strategy to advance early-stage academic research into drug candidates ready for clinical development. 4 November 2025
Biotechnology
Tuesday is shaping up to be another dark day in the stock market for US genetic medicines company Sarepta Therapeutics as key trial data were announced. 4 November 2025
Pharmaceutical
Pfizer today announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk in the US District Court for the District of Delaware. 3 November 2025
Biotechnology
US clinical-stage CRISPR genome-editing company Caribou Biosciences today announced positive results from its ongoing ANTLER Phase I clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). 3 November 2025
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Biotechnology
UK-based neuropsychiatry company Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as president and chief executive. 3 November 2025
Pharmaceutical
UK-based specialty CNS-focused pharma company CNX Therapeutics says it has acquired the global Sativex (nabiximols) business from USA-based Jazz Pharmaceuticals. 3 November 2025
Pharmaceutical
US pharma giant Pfizer revealed on Friday that it has filed a lawsuit against Metsera, its board of directors, and Denmark’s Novo Nordisk in the Delaware Court of Chancery. 1 November 2025
Biotechnology
Germany-based biotech Tubulis today announced a second and final closing of its Series C round totaling 344 million euros ($401million). 30 October 2025
Pharmaceutical
Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the company advances its first antibody-drug conjugate (ADC), VLX-ADC-001, toward candidate selection. The move signals VALANX’s shift from technology development to therapeutic application of its GoldenSite platform. 30 October 2025
Pharmaceutical
Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to outbid US pharma giant Pfizer, which just last month announced its own offer to acquire Metsera. 30 October 2025
Biotechnology
Swiss drug developer Oculis Holding today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. 30 October 2025
Biotechnology
US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer. 29 October 2025
Biotechnology
US clinical stage biotech Armata Pharmaceuticals’ investigational phage therapy, AP-SA02, demonstrated earlier resolution in patients with Staphylococcus aureus bacteremia (SAB) in a Phase IIa trial, reinforcing the growing clinical promise of bacteriophage-based treatments. 29 October 2025
Biotechnology
US biotech Zag Bio announced the company’s launch with $80 million in financing, including a recently closed Series A financing. 29 October 2025
Biotechnology
Australian biotech Myrio Therapeutics has joined forces with the University of Pennsylvania’s Perelman School of Medicine and NYU Langone Health to accelerate the development of next-generation immunotherapies for solid tumors. 29 October 2025
Pharmaceutical
China-headquartered Innovent Bio has announced that the fourth Phase III trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint. 28 October 2025
Pharmaceutical
Boston, USA-based Modulight Biotherapeutics, a developer of novel optogenetic platform for the treatment of neurological disorders, today announced the closing of its Seed funding round raising $12.2 million. 12 November 2025
Biotechnology
Texas, USA-based clinical-stage biotech March Biosciences announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, the company’s first-in-class autologous CD5-targeted CAR-T cell therapy, in development for relapsed/refractory CD5-positive T-cell lymphoma. 12 November 2025
Pharmaceutical
US biotech Cogent Biosciences has seen its share price more than double after its lead drug, bezuclastinib, delivered strong Phase III results in combination with sunitinib for patients with gastrointestinal stromal tumors (GIST) resistant or intolerant to Gleevec (imatinib). 11 November 2025
Biotechnology
US biotech Inovio said it plans to offer and sell shares of its common stock in an underwritten public offering, with all shares sold directly by the company. Underwriters will have a 30-day option to purchase up to 15% additional stock under the same terms. 11 November 2025
Biotechnology
Canadian genetic medicines company enGene Holdings saw its shares rocket as much as 65% to $9.93 in pre-market trading, after it reported additional preliminary data from the pivotal cohort of its ongoing, Phase II LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70). 11 November 2025
Pharmaceutical
US biopharma Madrigal has announced positive two-year data from the open-label compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis (F4c) arm of the Phase III MAESTRO-NAFLD-1 trial, evaluating the use of Rezdiffra (resmetirom) in an advanced, difficult-to-treat patient population with no approved therapies. 11 November 2025
Pharmaceutical
Switzerland’s Idorsia has announced the publication of a new analysis from the landmark Phase III PRECISION study. 11 November 2025
Pharmaceutical
US immunology specialist Celldex has appointed Teri Lawver as senior vice president, chief commercial officer. 11 November 2025
Pharmaceutical
US biopharma BridgeBio Pharma has presented data from the ATTRibute-CM study, showing that acoramidis significantly reduces all-cause mortality (ACM) through month 42 in the overall variant ATTR-CM population, and specifically in the p.Val142Ile (V142I, V122I) subpopulation. 10 November 2025
Biotechnology
US oncology company Summit Therapeutics and its partner Akeso have communicated results from the Phase III HARMONi-A trial -conducted in China and sponsored by the latter firm - featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. 10 November 2025
Biotechnology
French biotech EVerZom has signed its first research partnership with compatriot GENFIT to evaluate EViv, an exosome-based drug candidate for acute-on-chronic liver failure (ACLF), a life-threatening condition with few treatment options beyond transplantation. GENFIT will oversee preclinical testing, with an 18-month decision window on clinical development rights. 10 November 2025
Pharmaceutical
The last week or so has seen an escalation of the bidding war for US obesity-focused Metsera, with counter bids and law suits galore, but now that battle is over. 8 November 2025
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has announced the pricing of a $75 million underwritten offering. 6 November 2025
Biotechnology
US mRNA-based therapeutics company Strand Therapeutics has announced the promotion of Prashant Nambiar to chief scientific officer and appointment of Ethan Cash as senior vice president, head of portfolio management and program development. 6 November 2025
Biotechnology
California, USA-based clinical-stage biotech Braveheart Bio has announced its launch with $185 million in Series A financing, which will support development of an investigation treatment for hypertrophic cardiomyopathy. 6 November 2025
Pharmaceutical
Arena BioWorks, a privately funded biomedical research institute that aimed to overhaul the traditional drug discovery model, has closed its doors less than two years after its $500 million launch. The decision follows what its founding investor group called “dramatic changes” in biotech market conditions, with no clear recovery in sight. 6 November 2025
Pharmaceutical
Australian biotech PolyActiva and USA-based RareSight have formed a strategic collaboration to create first-in-class treatments for inherited retinal diseases in children. The research will apply PolyActiva’s proprietary Prezia sustained-release platform to generate new pro-drugs that can be delivered directly to the retina. 6 November 2025
Pharmaceutical
A Delaware vice chancellor on Wednesday refused Pfizer emergency bid for a temporary restraining order to block Metsera from closing a now $10 billion competing bid by Novo Nordisk for the GLP-1 weight-loss drugmaker, saying that Pfizer has not demonstrated Metsera's board acted in bad faith or that the company would suffer immediate irreparable harm. 6 November 2025
Biotechnology
California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary enveloped delivery vehicle (EDV) technology. 5 November 2025
Biotechnology
US biopharma firm Viridian Therapeutics today announced the successful submission of its biologics license application (BLA) to the US Food and Drug Administration (FDA) for veligrotug, the company’s investigational therapy for the treatment of thyroid eye disease (TED). 5 November 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze